Lung Cancer | Specialty

PARP Inhibitor Shows Potential in Squamous Cell Lung Cancer

October 26th 2014

Suresh S. Ramalingam, MD, discusses results from a phase II trial exploring the potential of veliparib as a treatment for patients with squamous cell NSCLC.

New Treatment Strategies Emerge for Non-Small Cell Lung Cancer

October 19th 2014

The treatment of patients with non-small cell lung cancer (NSCLC) who harbor an actionable mutation in EGFR or ALK continues evolve, as clinical trials begin exploring next-generation agents and combination strategies.

Treatment Selection in Metastatic Prostate Cancer

October 16th 2014

Convincing Long-Term Survival With Abiraterone in mCRPC

October 16th 2014

Quality of Life and Survival With Abiraterone in CRPC

October 16th 2014

Researchers Discuss Novel Therapies in NSCLC

October 16th 2014

Latest News & Insight: October 16, 2014

October 16th 2014

ASCO Endorses Molecular Testing Guideline for Lung Cancer

October 14th 2014

ASCO has endorsed the CAP/IASLC/AMP guideline on molecular testing for patients with lung cancer, which recommends EGFR and ALK testing for all patients with lung adenocarcinoma or mixed histology with an adenocarcinoma component.

Dr. Halmos on Detecting Actionable Mutations in Patients With Lung Cancer

October 7th 2014

Balazs Halmos, MD, section chief of Thoracic Oncology at New York-Presbyterian Hospital/Columbia University Medical Center, comments on the detection of actionable mutations in patients with lung cancer.

Collaboration Joins Nivolumab With Targeted Therapies in NSCLC

October 7th 2014

A clinical trial collaboration between Novartis and BMS has resulted in the establishment of several novel combination trials involving the PD-1 inhibitor nivolumab and targeted therapies against ALK, c-MET, and T790M for patients with NSCLC.

FDA Grants Breakthrough Therapy Designation to AP26113 in NSCLC

October 2nd 2014

The highly selective ALK inhibitor AP26113 has been granted a Breakthrough Therapy Designation by the FDA for the treatment of patients with ALK-positive metastatic NSCLC who received prior treatment with crizotinib.

Dr. Rolfo Discusses the Potential Utility of Ceritinib

October 2nd 2014

Christian Rolfo, MD, PhD, MHBA, head, phase I clinical trials unit, Antwerp University Hospital, Belgium, discusses the potential utility of ceritinib.

Dr. Herbst on the Next Generation of Lung Cancer Trials

October 1st 2014

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses next generation lung cancer trials.

EGFR Pioneer Keeps Focus on Individualizing Patient Care in Lab and Clinic

October 1st 2014

As director of the Yale Cancer Center and physician-in-chief of the Smilow Cancer Hospital at Yale-New Haven, Thomas J. Lynch Jr, MD, wears many hats. And, having built a career united around two abiding goals of clinical discovery and personalized patient care, that's just the way he likes it.

Crizotinib Highly-Effective in ROS1-Rearranged NSCLC

September 29th 2014

Treatment with crizotinib (Xalkori) demonstrated an overall response rate (ORR) of 72% in patients with ROS1-rearranged non–small cell lung cancer (NSCLC), according to phase I data presented at the 2014 ESMO Congress and published in The New England Journal of Medicine.

Dr. Galbraith Discusses Phase I/II Results for AZD9291 in Advanced NSCLC

September 29th 2014

Susan Galbraith, MD, PhD, head, Oncology Innovative Medicine, AstraZeneca, discusses updated data from the ongoing phase I/II AURA study looking at AZD9291 for NSCLC.

Pembrolizumab Yields Durable Responses in Advanced NSCLC

September 28th 2014

Almost 60% of patients with advanced non–small cell lung cancer experienced tumor shrinkage when treated with the PD-L1 inhibitor pembrolizumab.

Vintafolide Added to Docetaxel Improves Survival in Folate Receptor-Positive NSCLC

September 28th 2014

Vintafolide in combination with docetaxel showed improvements in PFS and OS compared with single-agent docetaxel as second-line treatment of patients with folate receptor–positive NSCLC.

Anamorelin Improves Appetite, Slows Weight Loss in Lung Cancer

September 27th 2014

Patients with advanced lung cancer had improved appetite, less weight loss, and a significant increase in lean body mass when treated with the ghrelin agonist anamorelin.

Peter Emtage on the Combination of MEDI4736 and Tremelimumab for NSCLC

September 27th 2014

Peter Emtage, discusses a phase I open-label study evaluating the safety and tolerability of MEDI4736 in combination with tremelimumab for the treatment of patients with advanced non-small cell lung cancer.